Key statistics
As of last trade, Alvotech SA (Z45:FRA) traded at 9.56, 24.48% above the 52 week low of 7.68 set on Nov 07, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.54 |
---|---|
High | 9.56 |
Low | 9.54 |
Bid | 9.92 |
Offer | 10.15 |
Previous close | 9.28 |
Average volume | 142.86 |
---|---|
Shares outstanding | 301.48m |
Free float | 107.18m |
P/E (TTM) | -- |
Market cap | 3.35bn USD |
EPS (TTM) | -2.65 USD |
Data delayed at least 15 minutes, as of Sep 23 2024 08:59 BST.
More ▼
Announcements
- Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
- Alvotech tekur þátt í árlegri heilbrigðisráðstefnu fjárfestingabankans Morgans Stanley
- Alvotech skilar mettekjum og metframlegð á öðrum ársfjórðungi og á fyrri helmingi ársins
- Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024
- European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
- Lyfjastofnun Evrópu tekur til umsagnar umsókn um markaðsleyfi fyrir AVT06, fyrirhugaða líftæknilyfjahliðstæðu við Eylea
- Alvotech mun birta uppgjör fyrri árshelmings 2024 fimmtudaginn 15. ágúst nk. og streyma uppgjörsfundi föstudaginn 16. ágúst nk. kl. 12:00 að íslenskum tíma
- Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET
- STADA og Alvotech hefja sölu á Uzpruvo, fyrstu líftæknilyfjahliðstæðunni við Stelara í Evrópu
- STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe
More ▼